Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

From their previous commentary, Regeneron’s take on competition has been that the rising tide lifts all ships, more so if you have the leading market share. Certainly, a positive way to view it ...

Regeneron Pharmaceuticals ... The other promising drug is in their growing oncology pipeline, as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally ...

while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall.” What Yancopoulos seems to be dancing around is that ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall,” Regeneron president George Yancopoulos said.